Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | P2RY10 | O00398 | 3/20 | 0.33 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7019565 | 0.90 | ALDH1A1 (0.40) | ALDH1A1TDP1L3MBTL1P2RY10GPR34 | |
| SCHEMBL699087 | 0.86 | EPHX2 (0.37) | EPHX2CNR1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL7109291 | 0.85 | EGFR (0.40) | ALDH1A1TDP1 | |
| SCHEMBL9229451 | 0.84 | EPHX2 (0.41) | EPHX2CNR1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL13030430 | 0.84 | EPHX2 (0.41) | EPHX2CNR1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL78014 | 0.84 | EPHX2 (0.41) | EPHX2CNR1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL18929537 | 0.84 | EPHX2 (0.37) | EPHX2CNR1ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL9420192 | 0.82 | HDAC6 (0.37) | ALDH1A1TDP1 | |
| SCHEMBL22915501 | 0.81 | EPHX2 (0.38) | EPHX2CNR1P2RY10CNR2 | |
| SCHEMBL3016143 | 0.81 | EPHX2 (0.37) | EPHX2CNR1ALDH1A1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167336-A1 | ADHESIVE SHEET | NITTO DENKO CORPORATION (JP) | 2023-06-01 | — | — | US | disclosed |
| US-8277695-B2 | Reversibly thermochromic compositions | BASF SE (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20110180767-A1 | Reversibly thermochromic compositions | CIBA CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20060138391-A1 | Flame retardant composition comprising a phosphonic acid metal salt and a nitrogen containing compound | CIBA SPECIALTY CHEMICALS CORP. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110180767-A1 | Reversibly thermochromic compositions | C1R, C3AR1, C9 | EPHX2 3195/4885CNR1 300/4885ALDH1A1 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.